Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Regulatory News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)-Vectura Group plc amend

16 Sep 2021 17:35

RNS Number : 0699M
JPMorgan Securities Plc
16 September 2021
 

 AMENDMENT

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Vectura Group plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Joint financial adviser & joint Corporate Broker to Vectura Group PLC

(d) Date dealing undertaken:

10 September 2021

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

0.0271p ordinary

Purchase

 

Sale

390,690

 

300,445

1.6400 GBP

 

1.6390 GBP

1.6380 GBP

 

1.6380 GBP

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

0.0271p ordinary

Equity Swap

Decrease Long

 

 

Decrease Short

 

Increase Short

 

Opening a Long Position

 

 

Opening a Short Position

 

91,057

17,209

 

8,895

 

2,678

 

155,267

11,869

 

 

126,216

40,920

1.6380 GBP

1.6400 GBP

 

1.6379 GBP

 

1.6388 GBP

 

1.6380 GBP

1.6390 GBP

 

 

1.6380 GBP

1.6381 GBP

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

16 September 2021

Contact name:

Alwyn Basch

Telephone number:

020 7742 7407

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERFZGMLVVMGMZM
Date   Source Headline
6th Feb 20187:00 amRNSTransaction in Own Shares
5th Feb 20187:00 amRNSTransaction in Own Shares
2nd Feb 20187:00 amRNSTransaction in Own Shares
1st Feb 201811:15 amRNSVoting Rights and Capital
1st Feb 20187:00 amRNSTransaction in Own Shares
31st Jan 20187:00 amRNSTransaction in Own Shares
30th Jan 20187:00 amRNSTransaction in Own Shares
29th Jan 20187:00 amRNSTransaction in Own Shares
26th Jan 20187:00 amRNSTransaction in Own Shares
25th Jan 20187:00 amRNSTransaction in Own Shares
24th Jan 20187:00 amRNSTransaction in Own Shares
23rd Jan 20187:00 amRNSTransaction in Own Shares
22nd Jan 201812:06 pmRNSHolding(s) in Company
22nd Jan 20187:00 amRNSTransaction in Own Shares
19th Jan 20187:00 amRNSTransaction in Own Shares
18th Jan 201810:56 amRNSDirector/PDMR Shareholding
12th Jan 20187:00 amRNSTransaction in Own Shares
11th Jan 20187:00 amRNSTransaction in Own Shares
9th Jan 20187:00 amRNSTransaction in Own Shares
5th Jan 20187:00 amRNSTransaction in Own Shares
4th Jan 20187:00 amRNS2017 Pre-close Trading Update
2nd Jan 201810:27 amRNSVoting Rights and Capital
29th Dec 20171:30 pmRNSDirector/PDMR Shareholding
21st Dec 20177:00 amRNSTransaction in Own Shares
20th Dec 20171:10 pmRNSHolding(s) in Company
20th Dec 20177:00 amRNSVectura to present at J.P. Morgan Conference
19th Dec 20177:05 amRNSVoting Rights and Capital
19th Dec 20177:00 amRNSTransaction in Own Shares
13th Dec 20177:00 amRNSTransaction in Own Shares
12th Dec 20179:30 amRNSDirector/PDMR Shareholding
11th Dec 20177:00 amRNSTransaction in Own Shares
8th Dec 20177:00 amRNSTransaction in Own Shares
5th Dec 20177:00 amRNSTransaction in Own Shares
1st Dec 201710:29 amRNSTotal Voting Rights
29th Nov 20177:00 amRNSVectura appoints Non-Executive Director
28th Nov 20177:00 amRNSVectura Group announces Transaction in Own Shares
27th Nov 201712:12 pmRNSVectura comment on Ultibro® Breezhaler® FLASH data
27th Nov 20177:00 amRNSVectura Group announces Transaction in Own Shares
17th Nov 20177:00 amRNSVectura Group announces Transaction in Own Shares
16th Nov 20177:00 amRNSVectura Group announces Transaction in Own Shares
15th Nov 201711:22 amRNSHoldings in Company
15th Nov 20177:00 amRNSVectura Group announces Transaction in Own Shares
14th Nov 20177:00 amRNSShare buyback and cancellation
9th Nov 20172:04 pmRNSDirector/PDMR Shareholding
9th Nov 20177:05 amRNSHikma statement on ANDA for generic Advair(VR315)
1st Nov 20179:23 amRNSVoting Rights and Capital
24th Oct 20177:00 amRNSUltibro Breezhaler delivers strong growth in Q3
19th Oct 20171:17 pmRNSLaunch of SeebriT Neohaler® in the US
10th Oct 20179:31 amRNSDirector/PDMR Shareholding
4th Oct 20174:03 pmRNSPositive flutiform k-haler regulatory progress

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.